Why Your Pre-Bed HGH Injection Is Built For The Wrong Body

The liver is not always ready to convert growth hormone into IGF-1, and the time of day you inject determines whether that conversion happens efficiently or gets wasted on the wrong biological environment.

To understand why timing matters, you need the full chain first. Your pituitary gland releases growth hormone in pulses throughout the day, but roughly 70 percent of your total daily output happens during the deepest stage of sleep, which typically occurs one to two hours after you fall asleep. That pulse travels to the liver, and the liver converts it into something called IGF-1, which is insulin-like growth factor 1, the hormone actually responsible for tissue repair, muscle protein synthesis, and most of the effects people associate with growth hormone. The growth hormone itself is more of a signal than the active agent. The liver is where the work gets done.

Now here is where insulin enters the picture, because the liver's ability to convert growth hormone into IGF-1 is not constant. It depends heavily on the hormonal environment at the time growth hormone arrives.

When you eat, your pancreas releases insulin, and insulin acts as a kind of permissive signal at the liver, telling it to ramp up IGF-1 production in response to growth hormone. When you are fasted, or when insulin is low, that permissive signal is absent, and the conversion rate drops. This means the same dose of growth hormone produces different amounts of IGF-1 depending on whether insulin is present or not when the hormone peaks in your bloodstream.

This is the conversion window people are either hitting or missing.

When you inject growth hormone subcutaneously, the hormone does not enter your blood immediately. It absorbs slowly from the injection site, and based on pharmacokinetic data from subcutaneous injections in healthy men, the peak blood concentration arrives roughly three to four hours after you pin. That four-hour lag is the number that makes everything else make sense.

If you inject at 10 at night, growth hormone peaks in your blood around 2 in the morning. Two problems converge at that moment. First, your body's own pituitary pulse is already happening during that deep sleep window, so you are adding exogenous growth hormone directly on top of an endogenous pulse your body was already producing without any help. You are not filling a gap. You are doubling up on something that was never empty. Second, at 2 in the morning you have been fasted for hours, insulin is near its floor, and the liver's conversion machinery is sitting essentially idle. High growth hormone, low insulin, low IGF-1 output. That is the least efficient version of the transaction.

There is also a metabolic cost to that overlap. Growth hormone is what researchers call counter-regulatory, meaning it directly opposes the action of insulin, particularly at the liver. It does this by suppressing something called hepatic insulin sensitivity, which is the liver's responsiveness to insulin signals. When growth hormone spikes overnight, it blunts the liver's ability to respond to insulin in the hours that follow, which is why fasting glucose runs high the next morning and why people wake up feeling sluggish or foggy after a pre-bed pin. Research on nocturnal growth hormone spikes in diabetic subjects found this mechanism clearly: the overnight growth hormone pulses were directly responsible for what is called the dawn phenomenon, the rise in fasting glucose that appears in the early morning even without eating. You are essentially engineering a version of that every night you pin before bed.

The 1990 study that gave rise to the pre-bed protocol is worth looking at directly, because understanding who the subjects were explains everything. That study compared evening versus morning injections in patients who were growth hormone deficient, meaning their pituitary glands had stopped producing growth hormone entirely. They had no endogenous pulse at all, zero, by definition. In those patients, 24-hour IGF-1 levels came out essentially the same regardless of whether they injected in the morning or the evening. The researchers concluded timing did not matter for that population, and for that population they were right. When you have no natural pulse, there is no pulse to collide with and no free production you could be suppressing.

But the study was not designed for people with functioning pituitary glands, and applying its conclusion to that population is a category error.

If your pituitary is still firing, you are working with a different system entirely, and the morning fasted protocol is designed around that system. You inject first thing after waking, while you are still fasted, and you wait 30 to 60 minutes before eating your first meal. During that window, growth hormone is absorbing from the injection site and beginning to climb. When you eat, insulin rises in response to the meal, and by the time growth hormone peaks three to four hours later, insulin is already present at the liver. The liver is primed. The conversion happens at higher efficiency. IGF-1 output from the same dose of growth hormone is meaningfully better than it would be in a fasted, low-insulin environment.

At lower doses, a single morning injection captures most of the benefit. At doses of 4 IU or higher, splitting the injection between morning and late afternoon extends IGF-1 production across more of the day without interfering with the overnight pulse. The afternoon window, typically around 3 to 5 PM, gives you another conversion opportunity while still allowing growth hormone levels to clear before sleep begins, leaving the pituitary's natural pulse room to operate on its own.

The practical implication is straightforward. Morning fasted injection, eat 30 to 60 minutes later, split if you are running higher doses, and leave the overnight window alone because your own biology is already handling it without you.

The deeper point is that the pre-bed protocol was not wrong for the patients it was tested on. It was exactly right for people who had no endogenous production. The mistake was assuming that a protocol designed for a broken system would also be optimal for an intact one, and the two systems are not the same in the ways that matter most to IGF-1 conversion.

---

References

1. Van Cauter E, Plat L. (1996). Physiology of growth hormone secretion during sleep. J Pediatr 128(5 Pt 2):S32-37. DOI: 10.1016/s0022-3476(96)70008-2
2. Jorgensen JO, Moller N, Moller J, Weeke J, Christiansen JS. (1985). Pharmacokinetics of biosynthetic authentic human growth hormone in normal men after subcutaneous or intramuscular injection. Acta Endocrinol (Copenh). PMID: 4034296
3. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. (1990). Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 70(1):207-14. PMID: 2294131. DOI: 10.1210/jcem-70-1-207
4. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. PMID: 19240267. DOI: 10.1210/er.2008-0027
5. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. (1990). Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33(1):52-9. PMID: 2406181. DOI: 10.1007/BF00586461

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness